このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS (DRINOTES)

2026年11月2日 更新者:University Hospital, Clermont-Ferrand

Proof-of-Concept Study Evaluating the Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS Requiring Surgical Treatment.

Polycystic Ovary Syndrome (PCOS) is a common condition among young women (the leading endocrine disorder) and is responsible for 70% of anovulatory infertility cases. Clinically, it has been defined since 2003 by the Rotterdam criteria, according to the French College of Obstetricians and Gynecologists. PCOS represents a significant challenge in reproductive medicine, as it is associated with infertility rates ranging from 20% to 74%. Ovarian stimulation is the first-line treatment for PCOS, as no etiological treatment is available. The first-line pharmacological treatment is Clomiphene Citrate. In cases where Clomiphene Citrate fails, the second-line treatment is ovarian drilling. Traditionally, ovarian drilling was performed via laparoscopy or fertiloscopy. Fertiloscopy had the advantage of being quicker and scarless for patients, with reported failure and conversion rates to laparoscopy of 10% to 20% depending on the studies. However, fertiloscopy is no longer practiced due to the discontinuation of the device. With the advent of vNOTES laparoscopy (Vaginal Natural Orifice Transluminal Endoscopic Surgery) in the 2010s for benign gynecological conditions, the possibility of a new vaginal approach for ovarian drilling is now being considered. The Primary Objective is to Evaluate the efficacy of ovarian drilling via vNOTES laparoscopy in terms of resumption of spontaneous ovulatory cycles in PCOS patients requiring surgical treatment.

Study Type:

Single-center, randomized, controlled, two-arm, proof-of-concept study. Number of Centers: 1

Study Description:

During the gynecology consultation, if an indication for ovarian drilling is established, the patient will be invited to participate in the study protocol. The study information sheet, detailing the study procedures and objectives, along with the consent form, will be provided to the patient.

A second consultation with the investigator will be scheduled to address any questions following a reflection period. If the patient consents, both she and the investigator will sign the consent form.

Randomization will be conducted using REDCap® software. The patient will then be assigned to either the vNOTES group or the laparoscopy group. Surgery will be performed by surgeons designated as "experts" in the respective surgical approach. The procedure will follow the standard techniques of the department.

Ovulatory cycle resumption will be assessed 6 months postoperatively during a follow-up consultation.

調査の概要

詳細な説明

Latest State of Scientific Knowledge Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in young women (5% of women of reproductive age) and is responsible for 70% of anovulatory infertility cases.

Since 2003, it has been defined according to the College of Obstetricians and Gynecologists of France by the Rotterdam criteria, which were revised by ESHRE in 2023.

According to these criteria, to diagnose PCOS, it is necessary to present at least two of the following three criteria and to have excluded other diagnoses:

Menstrual cycle abnormalities (amenorrhea, oligomenorrhea, long cycles) Clinical (hirsutism, acne, hair loss) or biological hyperandrogenism (elevated levels of free and total testosterone) Presence of polycystic ovaries on ultrasound: at least 12 follicles measuring 2 to 9 mm in diameter in each ovary or more than 20 follicles regardless of size. The number of follicles is more relevant than ovarian volume .

PCOS is a significant concern for reproductive medicine as it is associated with 20% to 74% infertility due to arrested follicular maturation caused by a multifactorial mechanism, particularly involving hyperandrogenism caused by excessive androgen production by the ovarian theca cells.

Ovarian stimulation is the first-line treatment for infertility related to PCOS as there is no etiological treatment. The first-line treatment is Clomiphene Citrate. It is a SERM that acts by inhibiting the negative feedback of estrogens on FSH. In case of failure, second-line treatment is ovarian drilling or gonadotropin stimulation according to ESHRE 2018 recommendations. Ovarian drilling involves making perforations in the ovarian stroma to destroy approximately 5% of the cortex of each ovary. It is recommended to use bipolar energy rather than monopolar or CO2 laser energy to reduce the risk of adhesions. Moreover, bipolar energy decreases the diffusion of energy compared to monopolar, thus limiting the reduction of the ovarian follicle pool. Although the mechanism remains unclear, it appears that the destruction of ovarian stroma by microperforations reduces androgen levels, increases FSH levels, and promotes follicular maturation.

The first ovarian drilling by laparoscopy was described in 1984 by Gjonnaess and his team. It was traditionally performed via laparoscopy or fertiloscopy. The latter technique is no longer practiced due to the discontinuation of the device.

More recently, in the 2010s, a new minimally invasive laparoscopic technique, vNOTES (Vaginal Natural Orifice Transluminal Endoscopic Surgery), was developed, using a natural orifice: the vagina. This method was first developed in Taiwan in 2012, then in Belgium.

With the development of the vNOTES laparoscopic technique for benign gynecological pathologies, particularly adnexal pathologies, the question arises of a new approach for ovarian drilling. Indeed, data on its use in the context of ovarian drilling are very limited, but initial results show a minimally invasive approach with good access to the pelvic cavity, minimal scarring, and reduced postoperative pain . The ovarian drilling technique using vNOTES was recently described by Professor Fernandez and his team and presented in a video at the SCGP congress in 2022 .

Hypotheses and Objectives The study is based on the hypothesis that ovarian drilling via vaginal vNOTES laparoscopy is at least as effective as the conventional laparoscopic technique in terms of resumption of ovulatory cycles. The objective is to evaluate the effectiveness of vaginal vNOTES laparoscopy compared to abdominal laparoscopy for ovarian drilling in women with polycystic ovary syndrome undergoing medically assisted reproduction.

Summary of Expected Benefits and Risks for Participants Expected benefits for patients in the VNotes group: shorter operative duration, less significant pain evolution, and aesthetic benefits.

Risks: The risks are those associated with anesthesia and surgery: hemorrhage, infection, digestive, vascular, or urinary tract injury, vaginal scar dehiscence. The additional risks of laparoscopy are those associated with trocars: hemorrhage, infection, herniation, and scar dehiscence.

The additional risk of vNOTES is the inability to complete the procedure, requiring conversion to laparoscopy.

Expected Outcomes If the ovarian drilling technique via VNotes proves to be as effective as laparoscopy, it would legitimize the development of an innovative technique combining good anatomical visualization, absence of abdominal scarring, and better outcomes in the context of assisted reproduction, as well as improved postoperative recovery for patients, with equivalent results in terms of ovulation resumption and pregnancy.

研究の種類

介入

入学 (推定)

48

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~43年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • PCOS defined by Rotterdam criteria requiring ovarian drilling after failure of first-line medical treatment
  • Primary or secondary infertility
  • Able to provide informed consent to participate in the research

Exclusion Criteria:

  • History of ovarian drilling
  • History of multiple pelvic surgeries
  • Current pregnancy or breastfeeding
  • Need for another associated surgical procedure other than hysteroscopy (hysteroscopy, neostomy)
  • Other infertility factors requiring IVF management
  • Contraindication to either surgical approach (laparoscopy or vNOTES):
  • History of upper genital tract infection
  • Confirmed or suspected recto-vaginal endometriosis on clinical examination
  • History of rectal surgery
  • Promontofixation
  • Virgin patient
  • Any concomitant pathology deemed incompatible with the study
  • Patients not affiliated with the social security system
  • Patients not speaking French
  • Patients under guardianship, curatorship, deprived of liberty, or under judicial protection
  • Refusal to participate

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:ovarian drilling by abdominal laparoscopy

Ovarian drilling procedure by abdominal laparoscopy

1st stage of surgery Patient in gynecological position, double skin cleansing with alcoholic Betadine and vaginal cleansing with dermal Betadine, placement of sterile drapes.

Urinary evacuation catheterization. Introduction of a diagnostic hysteroscope via vaginoscopy. Progress through the cervical canal. Exploration of the uterine cavity. Cannulation using a manipulator to perform a tubal blue test. 2nd stage of surgery: Patient in supine position, legs slightly abducted and semi-flexed. Insufflation of pneumoperitoneum in left hypochondrium with Palmer needle after satisfactory syringe safety test, up to a pressure of 20 mmHg. Trans-umbilical coeliotomy allowing passage of a 10 mm optical trocar after infiltration of the tract with Naropein 7.5 mg/ml.

Placement of two 5 mm operating trocars in the left iliac fossa and suprapubic area after infiltration of the tracts with Naropein 7.5 mg/ml.

Single-stitch closure with Filapeau 3/0.

Ovarian drilling procedure by abdominal laparoscopy versus ovarian drilling procedure by laparoscopic Vnotes .

see each arm for details for each intervention

実験的:Ovarian drilling by vaginal laparoscopy VNotes

Patient in gynecological position, double scrubbing of skin with alcoholic Betadine and vaginal with dermal Betadine, sterile drapes in place Urinary evacuation catheterization Introduction of a diagnostic hysteroscope via vaginoscopy Progress through the cervical canal Exploration of the uterine cavity Para-cervical block, uterine cannulation using a manipulator or a pediatric foley probe to perform a tubal blue test.

Placement of a Pozzi on the posterior lip of the cervix. Vaginal incision 1 cm below the cervix for 2 cm, opening the peritoneum with scissors vNOTES Gelpoint device inserted Trendelenburg position Insufflation of pneumoperitoneum(8 mm Hg) Exploration of abdominal cavity Bilateral ovarian drilling; approx. 12 to 15 micro-perforations on each side using the bipolar Versapoint inserted in the Bettochi and regular saline instillation Systematic tubal blue test Removal of the device Exsufflation of pneumoperitoneum Closure of the cul de sac of Douglas with a MONOCRYL 2/0

Ovarian drilling by vaginal laparoscopy VNotes

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The resumption (or not) of an ovulatory cycle
時間枠:at the 6 months follow-up visit

The resumption (or not) of an ovulatory cycle will be evaluated during the 6 months follow-up visit after the intervention. The resumption of cycles is defined by cycles lasting more than 3 months, an elevated progesterone level, or the presence of a corpus luteum on ultrasound."

at the 6 months follow-up visit

二次結果の測定

結果測定
メジャーの説明
時間枠
Pain assessment
時間枠:1 hour during ambulatory care

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 1 hour during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

1 hour during ambulatory care
pain assessment
時間枠:6 hours during ambulatory care

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient in the recovery room at 6 hours during ambulatory care. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

6 hours during ambulatory care
pain assessment
時間枠:on day 1 after the intervention

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient through a questionnaire sent to the patients on Day 1 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

on day 1 after the intervention
pain assessment
時間枠:on day 7 after the intervention

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient on Day 7 after the intervention. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

on day 7 after the intervention
pain assessment
時間枠:at the postoperative follow-up visit (1 month)

For each arm: Pain assessment using a VAS (Visual Analog Scale) requested from the patient during the postoperative follow-up visit. The scale ranges from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable

at the postoperative follow-up visit (1 month)
The use of analgesics
時間枠:up to 2 hours postoperatively

For each arm: The use of analgesics (yes/no) recorded up to 2 hours postoperatively

up to 2 hours postoperatively
The use of analgesics
時間枠:up to 24 hours postoperatively

For each arm: The use of analgesics (yes/no) recorded up to 24 hours postoperatively

up to 24 hours postoperatively
The use of analgesics
時間枠:postoperatively on Day 1

For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on Day 1.

postoperatively on Day 1
The use of analgesics
時間枠:postoperatively on Day 7

For each arm: The use of analgesics (yes/no) recorded postoperatively through a questionnaire sent to the patients on day 7

postoperatively on Day 7
The use of analgesics
時間枠:at the postoperative follow-up visit (1 month)

For each arm: The use of analgesics (yes/no) recorded at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
The operative duration
時間枠:peroperatively

For each arm: The operative duration from incision to closure recorded in the operating room, as well as the operative duration from the introduction of the Palmer needle in laparoscopy and the vaginal incision in VNotes until closure

peroperatively
Rehospitalization due to complications
時間枠:at the postoperative follow-up visit (1 month)

for each arm: Rehospitalization due to complications from the operation within the month following the procedure (yes/no), at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
Extension of the initial sick leave (yes/no)
時間枠:at the postoperative follow-up visit (1 month)

For each arm: Extension of the initial sick leave (yes/no), assessed at the postoperative follow-up visit (1 month)

at the postoperative follow-up visit (1 month)
The presence of intraoperative complications
時間枠:during the intervention

for each arm: The presence of intraoperative complications recorded during the intervention according to the Clavien-Dindo classification, including whether a conversion occurred, and the number of such complications

during the intervention
extension of the ambulatory stay (yes/no)
時間枠:Upon discharge from hospitalization (assessed up to 5 days)

For each arm: The use of an extension of the ambulatory stay (yes/no) and the total duration of hospitalization in days and hours

Upon discharge from hospitalization (assessed up to 5 days)
The occurrence of a pregnancy
時間枠:one year after the 6 months follow-up visit

The occurrence of a spontaneous pregnancy, IVF, twin pregnancy, or OHSS if IVF, assessed one year after the 6 months follow-up visit

one year after the 6 months follow-up visit
The measurement of AMH
時間枠:at the preoperative visit (1 month before the intervention)

The measurement of AMH in nanograms/mL at the preoperative visit (1 month before the intervention)

at the preoperative visit (1 month before the intervention)
The measurement of AMH
時間枠:at the postoperative follow-up visit (1 month)

The measurement of AMH in nanograms/mL at the postoperative follow-up visit (1month).

at the postoperative follow-up visit (1 month)
The measurement of AMH
時間枠:at the 6 Months follow-up visit

The measurement of AMH in nanograms/mL at the Month 6 follow-up visit

at the 6 Months follow-up visit
Satisfaction assessment
時間枠:at the postoperative follow-up visit (1 month)

Satisfaction assessment through the SF-36 questionnaire at the postoperative follow-up visit

at the postoperative follow-up visit (1 month)
Satisfaction assessment
時間枠:at the 6 Months follow-up visit

Satisfaction assessment through the SF-36 questionnaire at the 6 Months follow-up visit

at the 6 Months follow-up visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Anne-Sophie Gremeau、University Hospital, Clermont-Ferrand

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年3月14日

一次修了 (推定)

2030年9月14日

研究の完了 (推定)

2030年9月14日

試験登録日

最初に提出

2025年9月19日

QC基準を満たした最初の提出物

2026年11月2日

最初の投稿 (実際)

2026年11月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する